Prime Medicine, Inc.
PRME
$3.49
$0.195.61%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 486.12% | -- | 146.02% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 486.12% | -- | 146.02% | -- | -- |
| Cost of Revenue | 9.05% | -23.76% | 4.81% | -17.74% | -1.53% |
| Gross Profit | -6.56% | 50.18% | 34.30% | 23.01% | 2.04% |
| SG&A Expenses | -20.52% | 4.09% | 19.05% | -5.98% | 34.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.39% | -2.12% | 10.04% | -14.92% | 5.79% |
| Operating Income | 0.48% | 4.12% | -8.38% | 18.92% | -5.39% |
| Income Before Tax | 3.69% | 5.17% | -13.73% | 35.60% | -3.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.69% | 4.95% | -13.39% | 35.60% | -3.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.69% | 4.95% | -13.39% | 35.60% | -3.57% |
| EBIT | 0.48% | 4.12% | -8.38% | 18.92% | -5.39% |
| EBITDA | 1.10% | 4.84% | -7.80% | 20.25% | -4.88% |
| EPS Basic | 28.14% | 12.30% | 9.47% | 54.51% | 20.58% |
| Normalized Basic EPS | 26.52% | 11.75% | 14.22% | 44.11% | 19.39% |
| EPS Diluted | 28.14% | 12.30% | 9.47% | 54.51% | 20.58% |
| Normalized Diluted EPS | 26.52% | 11.75% | 14.22% | 44.11% | 19.39% |
| Average Basic Shares Outstanding | 34.02% | 8.39% | 25.29% | 41.59% | 30.40% |
| Average Diluted Shares Outstanding | 34.02% | 8.39% | 25.29% | 41.59% | 30.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |